Pharma BD Deal Intelligence

Eli Lilly and Company / ImmuNext Inc. (anti-VISTA license)

2019 · Licensing/Option · $350M · Complete

Announcement Sentiment

Strongly positive

Lilly licensed exclusive worldwide rights to a preclinical, first-in-pathway antibody targeting a novel immunometabolism pathway (lymphocyte metabolism reprogramming) from ImmuNext for autoimmune diseases. Upfront $40M; up to ~$565M in development and commercialization milestones; mid-single to low-double digit tiered royalties. Distinct from ImmuNext's VISTA checkpoint regulator program (partnered separately with Janssen for cancer and Roche for autoimmune).

Key facts

Announced Mar 26, 2019
Deal value $350M
Deal type Licensing/Option
Therapeutic area Autoimmune diseases
Indications Autoimmune diseases
Key assets Undisclosed preclinical immunometabolism antibody
Mechanism First-in-pathway antibody targeting lymphocyte immunometabolism (immune cell metabolism reprogramming)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals